Venous thromboembolism risk score during hospitalization in pregnancy: results of 10694 prospective evaluations in a clinical trial
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Citação
CLINICS, v.78, article ID 100230, 7p, 2023
Resumo
Objectives: Hospitalization during pregnancy and childbirth increases the risk of Venous Thromboembolism Risk (VTE). This study applied a VTE risk score to all hospitalized pregnant women to ascertain its effectiveness in pre -venting maternal death from VTE until 3 months after discharge.Methods: In this interventional study, patients were classified as low-or high-risk according to the VTE risk score (Clinics Hospital risk score). High-risk patients (score & GE; 3) were scheduled for pharmacological Thromboprophy-laxis (TPX). Interaction analysis of the main risk factors was performed using Odds Ratio (OR) and Poisson regres-sion with robust variance.Results: The data of 10694 cases (7212 patients) were analyzed; 1626 (15.2%, 1000 patients) and 9068 (84.8%, 6212 patients) cases were classified as high-risk (score & GE; 3) and low-risk (score < 3), respectively. The main risk factors (Odds Ratio, 95% Confidence Interval) for VTE were age & GE; 35 and < 40 years (1.6, 1.4-1.8), parity & GE; 3 (3.5, 3.0-4.0), age & GE; 40 years (4.8, 4.1-5.6), multiple pregnancies (2.1, 1.7-2.5), BMI & GE; 40 kg/m2 (5.1, 4.3-6.0), severe infection (4.1, 3.3-5.1), and cancer (12.3, 8.8-17.2). There were 10 cases of VTE: 7/ 1636 (0.4%) and 3/9068 (0.03%) in the high-and low-risk groups, respectively. No patient died of VTE. The inter-vention reduced the VTE risk by 87%; the number needed to treat was 3.Conclusions: This VTE risk score was effective in preventing maternal deaths from VTE, with a low indication for TPX. Maternal age, multiparity, obesity, severe infections, multiple pregnancies, and cancer were the main risk factors for VTE.
Palavras-chave
Venous thromboembolism, Hospitals, Pregnancy, Risk factors, Maternal death, Neoplasms
Referências
- [Anonymous], 2018, Obstet Gynecol, V131, pe49, DOI 10.1097/AOG.0000000000002501
- [Anonymous], 2020, PUBL HLTH WEB SER BL
- Bandolier, NUMB NEED TREAT
- Bates SM, 2018, BLOOD ADV, V2, P3317, DOI 10.1182/bloodadvances.2018024802
- Bates SM, 2016, J THROMB THROMBOLYS, V41, P92, DOI 10.1007/s11239-015-1309-0
- Burrows RF, 2001, BRIT J OBSTET GYNAEC, V108, P835, DOI 10.1111/j.1471-0528.2001.00198.x
- Cavazza S, 2012, THROMB RES, V129, P28, DOI 10.1016/j.thromres.2011.06.028
- Chan WS, 2014, J OBSTET GYNAECOL CA, V36, P527, DOI 10.1016/S1701-2163(15)30569-7
- Clinicaltrials.gov, THROMB PREGN WOM HOS
- Cox S, 2019, J THROMB HAEMOST, V17, P1160, DOI 10.1111/jth.14452
- Dargaud Y, 2017, J THROMB HAEMOST, V15, P897, DOI 10.1111/jth.13660
- Gassmann N, 2021, J THROMB HAEMOST, V19, P452, DOI 10.1111/jth.15166
- Hase EA, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e368
- Heit JA, 2017, BLOOD, V130, P109, DOI 10.1182/blood-2016-12-758995
- Jacobsen AF, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.08.041
- Jacobson B, 2020, ADV THER, V37, P27, DOI 10.1007/s12325-019-01124-z
- Klovaite J, 2015, J INTERN MED, V277, P573, DOI 10.1111/joim.12299
- Lobastov K, 2021, ANN SURG, V274, P63, DOI 10.1097/SLA.0000000000004556
- Middeldorp S, 2022, HAMOSTASEOLOGIE, V42, P54, DOI 10.1055/a-1717-7663
- Nagata C, 2015, J OBSTET GYNAECOL RE, V41, P1440, DOI 10.1111/jog.12740
- Nicholson M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082467
- Nuovo J, 2002, JAMA-J AM MED ASSOC, V287, P2813, DOI 10.1001/jama.287.21.2813
- Poggio F, 2020, CANCERS, V12, DOI 10.3390/cancers12123616
- Royal College Obstetricians and Gynaecologists, 2015, RED RISK VEN THROMB, P1
- Sultan AA, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6253
- Sultan AA, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6099
- Vandvik PO, 2012, AM COLL CHEST PHYS E, V141, p691S
- Virkus RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096495
- Walker AJ, 2016, BLOOD, V127, P849, DOI 10.1182/blood-2015-01-625582